Viatris (VTRS) closed at $20.28 on November 18, 2026, down 0.8% from the previous close, on volume of 12,185,724 shares (30-day average 9,253,595).
Data as of November 18, 2026.
18-Nov-2026
| # | Date | Strategy | Legs | Contracts |
|---|---|---|---|---|
| 1 | Nov 11, 2026 | Covered Call | 15-Jan-27 10 C +5,021,900 Stock | 50,219 |
| 2-2 | The next 1 largest trades are for Premium members. Start a 7-day free trial | |||
Ranked by contracts: multi-leg trades of 200 or more contracts on one day, through Nov 17, 2026. See the largest for 5, 30, 60 and 90 days
Analysts Are Bullish on These Healthcare Stocks: Natera (NTRA), Tango Therapeutics (TNGX)
TipRanks (Wed, 18-Nov 8:21 AM ET)
Viatris Completes Acquisition of Pacira BioSciences, Expanding Pain Management Portfolio
TipRanks (Tue, 17-Nov 10:23 AM ET)
Viatris Completes Acquisition of Pacira BioSciences
PRNewswire (Tue, 17-Nov 8:50 AM ET)
Glenview ups stakes in Meta, Teva; cuts CVS, Block in Q3; exits DKS, STM
Seeking Alpha News (Tue, 17-Nov 5:18 AM ET)
U.S. stock futures lower as investors brace for Nvidia results
Seeking Alpha News (Tue, 17-Nov 4:19 AM ET)
Einhorn's DME exits PayPal, Stubhub, adds Century Aluminum, among Q3 moves
Seeking Alpha News (Mon, 16-Nov 6:46 PM ET)
A $1.65 Billion Buyout Deal Puts a Spotlight on PolyPid Ahead of Its FDA Decision (NASDAQ: PYPD)
TipRanks (Mon, 16-Nov 9:10 AM ET)
CADILLAC FORMULA 1 TEAM WELCOMES VIATRIS AS OFFICIAL GLOBAL PHARMACEUTICAL PARTNER
PRNewswire (Mon, 16-Nov 9:00 AM ET)
Viatris Named to Fortune's World's Best Workplaces List for Second Consecutive Year
PRNewswire (Thu, 12-Nov 8:00 AM ET)
Ingram Micro Holding Set to Join S&P SmallCap 600
PRNewswire (Wed, 11-Nov 6:51 PM ET)
Viatris was formed in November 2020 through the combination of Upjohn, a wholly owned subsidiary of Pfizer that specialized in off-patent drugs, and Mylan, a global pharmaceutical manufacturer that focused on generic and specialty drugs. By joining forces, Viatris became one of the largest generic drug manufacturers in the world, servicing over 165 countries. Generics (commoditized and complex) and biosimilars make up one-third of Viatris' total sales. The remaining sales are derived from its portfolio of legacy products, including Lipitor, Norvasc, Lyrica, and Viagra.
Viatris trades on the NASDAQ stock market under the symbol VTRS.
As of November 18, 2026, VTRS stock price declined to $20.28 with 12,185,724 million shares trading.
VTRS has a beta of 0.32, meaning it tends to be less sensitive to market movements. VTRS has a correlation of 0.02 to the broad based SPY ETF.
VTRS has a market cap of $23.25 billion. This is considered a Large Cap stock.
Last quarter Viatris reported $4 billion in Revenue and $.71 earnings per share. This fell short of revenue expectation by $-37 million and exceeded earnings estimates by $.07.
In the last 3 years, VTRS traded as high as $21.20 and as low as $6.85.
The top ETF exchange traded funds that VTRS belongs to (by Net Assets): VTI, VOO, VB, IVV, VBR.
VTRS has outperformed the market in the last year with a price return of +94.7% while the SPY ETF gained +10.8%. VTRS has also outperformed the stock market ETF in the last 3 month and 2 week periods returning +25.7% and +7.2%, respectively, while the SPY returned -5.3% and -3.2%, respectively.
VTRS support price is $20.10 and resistance is $20.80 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that VTRS shares will trade within this expected range on the day.